Skip to main content
BrainCited

Omega-3 Fatty Acids (DHA/EPA) Age-Related Cognitive Decline

A

A systematic review of 58 studies found each 2,000 mg/day of omega-3 showed significant improvements in attention, perceptual speed, language, and primary memory. Research suggests a non-linear dose-response with optimal effects at moderate doses under 1,700 mg/day.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Domega\u002D3\u002Ddha\u002Depa\u0026condition\u003Dcognitive\u002Ddecline'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

結論

A systematic review of 58 studies found each 2,000 mg/day of omega-3 showed significant improvements in attention, perceptual speed, language, and primary memory. Research suggests a non-linear dose-response with optimal effects at moderate doses under 1,700 mg/day.

Key Study Findings

Systematic Review
Impact of Vegan and Vegetarian Diets on Neurological Health: A Critical Review.
Dose: None vs: None Outcome: Neurological health outcomes 効果: None None

対象集団: None

Review
Neuroprotective Role of Omega-3 Fatty Acids: Fighting Alzheimer's Disease.
Dose: None vs: None Outcome: None 効果: None None

対象集団: None

Review
Exploring the Efficacy and Safety of Nutritional Supplements in Alzheimer's Disease.
Dose: Curcumin 800mg/d, omega-3 2g/d, resveratrol 600mg/d vs: None Outcome: Cognitive decline in AD 効果: None None

対象集団: Alzheimer's disease patients

Review
Advanced nutraceutical approaches to Parkinson's disease: bridging nutrition and neuroprotection.
Dose: None vs: None Outcome: None 効果: None None

対象集団: None

Review
Nutrition, cognition and chronic kidney disease: A comprehensive review of interactions and interventions.
Dose: None vs: None Outcome: None 効果: None None

対象集団: None

In Vitro
Multiplatform Lipid Analysis of the Brain of Aging Mice by Mass Spectrometry.
Dose: None vs: None Outcome: Age-dependent brain lipid changes 効果: None None

対象集団: Mice: adult (3-4mo), middle-aged (10mo), old (19-21mo)

Key Statistics

58

研究数

12000

参加者数

Positive

A

グレード

Referenced Papers

Molecules (Basel, Switzerland) 2025 10 件の引用
Journal of Alzheimer's … 2025 3 件の引用
Nutrients 2025 2 件の引用
Current opinion in … 2023 58 件の引用
Nutrients 2022 76 件の引用
International journal of … 2022 23 件の引用
Current nutrition reports 2019 310 件の引用
Nutricion hospitalaria 2019 40 件の引用
American family physician 2018 101 件の引用
Nutricion hospitalaria 2018 32 件の引用
Advances in nutrition … 2017 215 件の引用
Nutricion hospitalaria 2014 17 件の引用
Advances in nutrition … 2013 155 件の引用
Current treatment options … 2011 6 件の引用
Molecular neurobiology 2010 145 件の引用
Women's health (London, … 2010 48 件の引用
JAMA 2010 3 件の引用
The Practitioner 2010
The Cochrane database … 2009 299 件の引用
Prostaglandins, leukotrienes, and … 2009 258 件の引用
Neuro endocrinology letters 2008
The Cochrane database … 2007 375 件の引用
Prostaglandins, leukotrienes, and … 2006 176 件の引用
Medecine sciences : … 2005 19 件の引用
The Cochrane database … 2003 263 件の引用
Journal of Alzheimer's … 2003 161 件の引用
Pharmacological research 1999 1060 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:
1,000-2,000 mg combined DHA/EPA per day
cognitivesupport:
1,000-1,700 mg/day (optimal dose-response curve)

上限量: 3,000 mg/day combined DHA/EPA (FDA GRAS)

研究で検討された用量

用量 期間 効果 N
None -- Mixed --
None -- Mixed --
Curcumin 800mg/d, omega-3 2g/d, resveratrol 600mg/d -- Mixed --
None -- Mixed --
None -- Mixed --
None -- Mixed --
Vit D 1 mcg/kg + N-3 PUFA 300 mg/kg EPA+DHA 4 weeks Positive 50
None -- Mixed --

推奨摂取タイミング: With meals containing fat for better absorption

Safety & Side Effects

報告されている副作用

  • Fishy aftertaste or burping
  • Mild gastrointestinal discomfort
  • Potential increased bleeding time at very high doses
  • May lower blood pressure slightly

既知の相互作用

  • Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
  • Blood pressure medications (additive hypotensive effect)
  • Orlistat (may reduce omega-3 absorption)

耐容上限摂取量: 3,000 mg/day combined DHA/EPA (FDA GRAS)

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Omega-3 Fatty Acids (DHA/EPA) help with Age-Related Cognitive Decline?
Based on 58 studies with 12,000 participants, there is strong evidence from multiple clinical trials that Omega-3 Fatty Acids (DHA/EPA) may support Age-Related Cognitive Decline management. Our evidence grade is A (Strong Evidence).
How much Omega-3 Fatty Acids (DHA/EPA) should I take for Age-Related Cognitive Decline?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined DHA/EPA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (DHA/EPA)?
Reported side effects may include Fishy aftertaste or burping, Mild gastrointestinal discomfort, Potential increased bleeding time at very high doses, May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (DHA/EPA) and Age-Related Cognitive Decline?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 58 peer-reviewed studies with 12,000 total participants. The overall direction of effect is positive.

Related Evidence

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。